跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
按專業知識、姓名或所屬機構搜尋
Quantitative benefit-harm assessment for setting research priorities: The example of roflumilast for patients with COPD
Milo A. Puhan,
Tsung Yu
, Cynthia M. Boyd, Gerben ter Riet
公共衛生學科暨研究所
研究成果
:
Article
›
同行評審
10
引文 斯高帕斯(Scopus)
總覽
指紋
指紋
深入研究「Quantitative benefit-harm assessment for setting research priorities: The example of roflumilast for patients with COPD」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Randomized Trial
100%
Benefit-risk Assessment
100%
Roflumilast
100%
Chronic Obstructive Pulmonary Disease
66%
Risk-benefit Ratio
66%
Value of Information Analysis
66%
Regulatory Agencies
33%
Medical Intervention
33%
Psychosocial Outcomes
33%
Patient Preference
33%
Value Types
33%
Specific Interventions
33%
Current Estimation
33%
Intervention Needs
33%
Social Sciences
Documentary Analysis
100%
Diseases
100%
Research Priorities
100%
Decision Making
50%
Regulatory Agency
50%
Nursing and Health Professions
Obstructive Lung Disease
100%
Roflumilast
100%
Practice Guideline
33%
Patient Preference
33%
Neuroscience
Chronic Obstructive Pulmonary Disease
100%
Roflumilast
100%
Decision-Making
33%
Psychology
Decision Making
100%
Economics, Econometrics and Finance
Regulatory Agency
50%